At BIOTTS we are gearing up for this year’s CPHI Worldwide event happening in Barcelona. It’s a fantastic opportunity to present the new possibilities of our innovative transdermal delivery technology, capable of transporting large molecules such as proteins and peptides through the skin. We’re thrilled to be a part of it! CPHI Worldwide serves as […]

We are thrilled to unveil our brand-new website, showcasing the revolutionary Multifunctional Transdermal Carrier Y (MTC-Y™) technology developed by Biotts, a global leader in Transdermal Drug Delivery. With a focus on transforming the landscape of drug delivery, Biotts has pioneered an innovative solution that facilitates the transdermal delivery of both lipophilic and hydrophilic molecules, including […]

Our Biotts team – Dr. Paweł Biernat, CEO & Transdermal Systems Specialist, and Jan Hendriks, CBO, took part in the annual conference Advanced Technologies & Treatments for Diabetes (ATTD) 2023 in Berlin. The event brought together developers of new technologies with distinguished diabetes professionals and caretakers, researchers, industries, startup companies, investors, reimbursement authorities and regulators, […]

It’s official: Biotts has reached another important milestone in its development! The Chief Pharmaceutical Inspectorate has granted Biotts a license to manufacture and import medicinal products – thanks to this consent, our scientists can start clinical trials on humans in the first quarter of 2023. The granting of a GMP license means that we’ve met […]

The 5 Forum Nowoczesnej Diabetologii (5th Forum of Modern Diabetology) has ended. One of the event’s highlights was a contest that featured the most innovative project/product supporting the treatment and self-management of patients with diabetes. We are excited to announce that this award went to the team from Biotts! Thank you again to the organizers for this awesome […]

We’re excited to let you know about another big “win” for Biotts: The Lower Silesia Voucher for Innovation will allow for the further development of our technology. – We will use the grant to analyze the molecular structure of our transdermal carrier. The subject of the study carried out by the University of Opole will […]